Is Beam Therapeutics Inc. (BEAM) a Buy, Sell, or Hold?
NASDAQ : BEAM
Beam Therapeutics Inc.
$25.1 USD
-$0.81 (-3.13%)
- Volume
- 1.81M
- Average Volume
- 2.43M
- Market Capitalization
- $2.58B
- P/E Ratio
- -39.22
- Dividend Yield
- 0.00%
- Price Target
- $56.50
- Year High
- $38.26
- Year Low
- $15.60
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $16.99
Company Overview
NASDAQ
John Evans
Biotechnology
Healthcare
BEAM
522
US
USD
Liquidity Metrics
0.22
16.99
16.99
3.87
0.00
Sales & Valuation
$139.74M
15.74
2.23
-6.73
-3.72
Profitability
-$0.81
-$79.99M
-39.66%
-39.66%
-5.89%
-4.39%
P/E Metrics
-39.22
-0.26
-0.26
Analyst Price Target & Rating
$56.50
$80.00
$26.00
1/5
27 Analysts
-55.58%
Financial Health Scores
4.21
3/9
$1.19B
$1.48B
$316.36M
-$54.4M
Key Metrics (TTM)
$2.54B
15.52
-79.45
16.99
-5.89%
-26.15%
-2.51%
-14.86%
-20 days
Company Executives
| Name | Title |
|---|---|
| Bethany J. Cavanagh | Senior VP of Finance, Treasurer & Principal Accounting Officer |
| David R. Liu | Co-Founder |
| Feng Zhang | Co-Founder |
| Amy Simon | Chief Medical Officer |
| J. Keith Joung | Co-Founder |
| Manmohan Singh | Chief Technology Officer |
| Christine Bellon | Chief Legal Officer & Corporate Secretary |
| John Evans | Chief Executive Officer & Director |
| Sravan Kumar Emany | Chief Financial Officer |
| Giuseppe Ciaramella | President |
Poll Results
No votes yet today — be the first to share your view!
About Beam Therapeutics Inc. (NASDAQ:BEAM) Stock
Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these fla ... gship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.
2026-07-23 07:00:00
CAMBRIDGE, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present updated clinical data from the Phase 1/2 trial evaluating BEAM-302 for alpha-1 antitrypsin deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026, taking place September 5–9, 2026, in Barcelona, Spain.
Beam Therapeutics Inc. (NASDAQ:BEAM) Given Average Rating of “Moderate Buy” by Brokerages
2026-07-23 02:15:35
Beam Therapeutics Inc. (NASDAQ: BEAM - Get Free Report) has received an average recommendation of "Moderate Buy" from the fourteen ratings firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating and ten have assigned a buy rating to the company.
2026-07-21 03:14:10
Amova Asset Management Americas Inc. lowered its stake in Beam Therapeutics Inc. (NASDAQ: BEAM) by 13.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,825,585 shares of the company's stock after selling 583,715 shares during the quarter. Beam Therapeutics makes
Cathie Wood Is Buying This Up-and-Coming Biotech Stock. Should You Follow Her Lead?
2026-07-20 13:30:00
Beam Therapeutics' growing pipeline could reward patient investors.
Prime Medicine Beats Beam Therapeutics In Patent Dispute - But Both Are Investable
2026-07-09 10:22:58
Prime Medicine, Inc. secured a favorable arbitration ruling against Beam Therapeutics, allowing continued development of its PM647 gene editing program for AATD. PRME's Prime Editing platform offers precise, versatile gene correction using LNP delivery, but remains preclinical with IND/CTA filings for PM647 expected mid-2026 and initial clinical data in 2027. PRME lags competitors like Beam, Sanofi, and Arrowhead in the AATD development race, facing significant funding needs and clinical risks.
Prime Medicine Secures Favorable Arbitration Ruling in Beam Therapeutics Case
2026-07-08 13:29:41
Prime Medicine Inc. (NASDAQ:PRME) said it secured a favorable, binding arbitration ruling in its dispute with Beam Therapeutics Inc. (NASDAQ:BEAM).
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics
2026-07-08 05:45:00
Gene-editing is a handy tool for developing sophisticated medicines. A new CRISPR molecule can destroy cells that express specific signals.
Powder Keg Stocks: 10 Most‑Shorted Names Primed For A Monster Squeeze
2026-06-29 10:35:25
Fresh short‑interest data for late June shows a tightly packed group of mid‑ and large‑cap names where bearish positioning has reached extreme territory, setting the stage for violent moves if sentiment flips.
Frequently Asked Questions
-
What is the current Beam Therapeutics Inc. (BEAM) stock price?
-
Beam Therapeutics Inc.(NASDAQ:BEAM) stock price is $25.1 in the last trading session. During the trading session, BEAM stock reached the peak price of $38.26 while $15.6 was the lowest point it dropped to. The percentage change in BEAM stock occurred in the recent session was --3.13% while the dollar amount for the price change in BEAM stock was -$0.81.
-
BEAM's industry and sector of operation?
-
The NASDAQ listed BEAM is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of BEAM?
-
Bethany J. Cavanagh | Senior VP of Finance, Treasurer & Principal Accounting Officer
David R. Liu | Co-Founder
Feng Zhang | Co-Founder
Amy Simon | Chief Medical Officer
J. Keith Joung | Co-Founder -
How many employees does BEAM have?
-
Number of BEAM employees currently stands at 522. BEAM operates from 238 Main Street, Cambridge, MA 02142, US.
-
Link for BEAM official website?
-
Official Website of BEAM is: https://www.beamtx.com
-
How do I contact BEAM?
-
BEAM could be contacted at phone #857 327 8775 and can also be accessed through its website. BEAM operates from 238 Main Street, Cambridge, MA 02142, US.
-
How many shares of BEAM are traded daily?
-
The average number of BEAM shares traded daily for last 3 months was 2.43M.
-
What is the market cap of BEAM currently?
-
The market value of BEAM currently stands at $2.58B with its latest stock price at $25.1